MANAGEMENT OF CARDIORENAL SYNDROME DEVELOPED IN CHRONIC HEART FAILURE

Berdiyeva Rano Sultonovna
Assistants:
Norkulov Zokir Urolovich
Tashkent Medical University, Termiz Branch
Department of Internal Diseases, Military Field Therapy, Hematology, and Family Medicine
https://doi.org/10.5281/zenodo.17837144

ARTICLE INFO

Received: 27th November 2025
Accepted: 28th November 2025
Online: 29th November 2025

KEYWORDS

digitization, modern education, teacher-student relations, teaching

ABSTRACT

Cardiorenal syndrome (CRS) is a complex clinical condition in which bidirectional pathophysiological interactions between the heart and kidneys cause functional impairment of one organ due to dysfunction of the other. CRS associated with chronic heart failure (CHF) is characterized by poor prognosis, frequent hospitalizations, and increased mortality. This thesis analyzes key mechanisms and modern treatment approaches for CRS related to CHF

Introduction. Cardiorenal syndrome (CRS) represents one of the most challenging clinical intersections in cardiovascular and renal medicine, particularly in the setting of chronic heart failure (CHF). Defined as a pathophysiological disorder of the heart and kidneys whereby acute or chronic dysfunction in one organ induces acute or chronic dysfunction in the other, CRS significantly worsens clinical outcomes, increases hospitalization rates, and elevates overall mortality. Over the past decade, the prevalence of CRS has continued to rise in parallel with global increases in heart failure incidence, aging populations, and comorbid conditions such as diabetes mellitus, hypertension, and obesity. Recent studies underscore that more than one-third of patients with chronic heart failure exhibit some degree of concomitant renal impairment, highlighting the critical need for integrated management strategies.

The complex interplay between hemodynamic alterations, neurohormonal activation, systemic inflammation, venous congestion, and impaired renal perfusion has been increasingly recognized as central to CRS pathogenesis. Contemporary research has shifted focus from simple volume-overload paradigms to more nuanced mechanisms involving renal venous hypertension, maladaptive activation of the renin–angiotensin–aldosterone system (RAAS), sympathetic nervous system overactivity, and cardiorenal metabolic dysregulation. These insights have catalyzed the development of new therapeutic approaches aimed not merely at improving cardiac output but also at preserving renal function and attenuating multisystem injury.

Management of CRS in the context of chronic heart failure has evolved substantially with the advent of novel pharmacological therapies, including sodium–glucose cotransporter 2 (SGLT2) inhibitors, angiotensin receptor–neprilysin inhibitors (ARNI), and nonsteroidal

mineralocorticoid receptor antagonists (MRAs), all of which have demonstrated renoprotective and cardioprotective benefits in recent trials. Additionally, there is growing emphasis on individualized hemodynamic assessment, optimization of diuretic strategies, and the integration of biomarkers and imaging modalities to guide therapy. Emerging evidence also supports the role of device-based interventions and advanced ultrafiltration techniques in selected patient populations.

Despite these advances, CRS remains a clinical condition with significant diagnostic and therapeutic complexity. Gaps persist regarding the timing, sequencing, and combination of available therapies, particularly in patients with advanced renal dysfunction or those who develop diuretic resistance. Continued research is essential to refine risk stratification tools, identify early markers of renal deterioration, and develop targeted therapies that address the shared cardiorenal axis.

This article reviews contemporary understanding of the pathophysiology of CRS in chronic heart failure and examines recent advances in its management, with an emphasis on evidence-based pharmacological, device-based, and supportive strategies aimed at improving long-term outcomes.

Type II cardiorenal syndrome commonly develops as a consequence of chronic heart failure and is associated with decreased renal perfusion, neurohormonal activation, and intensified inflammatory processes. In 25–40% of patients with CHF, varying degrees of renal dysfunction are present, complicating treatment.

Key Aspects of Pathogenesis

1.Hypoperfusion and Hemodynamic Changes:

Reduced cardiac output leads to decreased glomerular filtration in the kidneys.

2.Activation of the RAAS and Sympathetic Nervous System:

Increased angiotensin II and aldosterone levels not only raise blood pressure but also accelerate fibrotic changes in myocardial and renal tissues.

3.Inflammation and Oxidative Stress:

The rise in cytokines (IL-6, TNF-α) contributes to secondary damage to both the heart and kidneys.

Principles of Treatment

Management of cardiorenal syndrome requires a comprehensive approach that considers the interplay between the heart and kidneys.

1. Optimization of Hemodynamic Status

- Reduction of fluid overload using loop diuretics.
- In refractory cases, combination diuretic therapy or ultrafiltration may be used.

2. Neurohormonal Blockade

- ACE inhibitors or ARBs improve cardiac output and stabilize renal microcirculation.
- Beta-blockers (metoprolol, bisoprolol) reduce cardiac workload.
- Mineralocorticoid receptor antagonists (spironolactone, eplerenone) play an important role in reducing fibrosis.

3. Role of SGLT2 Inhibitors

Recent studies have shown that SGLT2 inhibitors such as dapagliflozin and empagliflozin help preserve renal function and reduce hospitalizations for heart failure in

patients with CHF-related CRS. They enhance diuretic effects, lower intraglomerular pressure, and improve cardiac metabolism.

4. Vasodilator and Inotropic Therapy

• Short-term inotropic support (dobutamine, levosimendan) may be used in cases of low perfusion.

• Nitrates reduce preload and improve hemodynamic parameters.

5. Renal Supportive Therapy

• Renal replacement therapy (RRT) is considered in cases of advanced azotemia, hyperkalemia, or diuretic-resistant edema.

• Individualized hydration management is essential for maintaining renal perfusion.

Conclusion. Cardiorenal syndrome associated with chronic heart failure is a complex pathophysiological condition that requires a multimodal treatment strategy. The use of SGLT2 inhibitors and neurohormonal blockers significantly improves the prognosis of this syndrome. Early diagnosis, regular monitoring, and individualized treatment are crucial for improving the quality of life and reducing mortality in patients with CRS.

References:

1.Almatov R., Karimov J. Pathophysiology of Cardiorenal Syndrome. Tashkent: Medpress, 2018.

2.McDonald P., Henry G. “Chronic Heart Failure and Kidney Interaction.” Journal of Cardio-Renal Medicine. 2019; 12(3): 44–58.

3.Shukurova N. “The Role of SGLT2 Inhibitors in Chronic Heart Failure.” Uzbekistan Medical Bulletin. 2022; 7(1): 15–21.

4.Braunwald E. Heart Failure: A Comprehensive Review. New York: McGraw-Hill, 2016.

5.European Society of Cardiology (ESC). “Guidelines for Heart Failure Management.” 2021. Accessed: 12.03.2023.